Drugs - Hematology and Oncology Flashcards Preview

USMLE > Drugs - Hematology and Oncology > Flashcards

Flashcards in Drugs - Hematology and Oncology Deck (42)
Loading flashcards...

Unfractionated heparin

MOA: activates antithrombin, decreasing thrombin and factor Xa; short half life

Use: immediate anticoagulation for PE, MI, DVT; used during pregnancy because does not cross placenta

Adverse effects: bleeding, heparin-induced thrombocytopenia (higher risk that LMWH or fondapurinix), osteoporosis; level increased with simultaneous isoniazid treatment

Antidote: protamine sulfate


Protamine sulfate

MOA: positively charged molecule that binds to negatively charged heparin

Use: heparin toxicity


Low molecular weight heparin

MOA: activates antithrombin, decreaseing factor Xa; better bioavailability than unfractionated and longer half life; admistered SC and requires less monitoring but not easily reversible

Use: immediate anticoagulation for PE, MI, DVT

Adverse effects: bleeding, heparin-induced thrombocytopenia, osteoporosis; level increased with simultaneous isoniazid treatment



MOA: synthetic factor that activates antithrombin, decreaseing factor Xa; better bioavailability than unfractionated and longer half life; admistered SC and requires less monitoring but not easily reversible

Use: immediate anticoagulation for PE, MI, DVT

Adverse effects: bleeding, heparin-induced thrombocytopenia, osteoporosis; level increased with simultaneous isoniazid treatment



MOA: interferes with gamma carboxylation of vitamin K dependent clotting factors (II, VII, IX, X, C, S) by affecting vitamin K epoxide reductase complex; increases PT through effect on extrinsic pathway; long half life and takes a few days to take effect, a few weeks to find proper therapeutic dose

Use: chronic anticoagulation to prevent thromboembolism; prevent stroke in setting of atrial fibrillation or mechanical valve; avoided in pregnancy; monitored with MT/INR

Adverse effects: bleeding, teratogenic, skin/tissue necrosis, early transient hypercoagulability due to faster effect on proteins C and S (often do heparin bridging to prevent); interactions with certain foods

Antidote: vitamin K


Apixaban and rivaroxaban

MOA: direct factor Xa inhibitors

Use: treat and prevent DVT and PE, superior for stroke prophylaxis in atrial fibrillation patients compared with warfarin; does not require coagulation monitoring

Adverse effects: bleeding with no available reversal agent



Drugs: tPA, rPA, streptokinase

MOA: aid conversion of plasminogen to plasmin, increasing both PT and PTT

Use: used in early MI, early ischemic stroke, and severe PE (within 3 hours)

Toxicity: bleeding

Antidote: toxicity treated with aminocaproic acid which prevents conversion of plasminogen to plasmin; can also use fresh frozen plasma and cryoprecipitate to correct associated factor deficiencies



MOA: irreversibly inhibits COX 1 and COX 2 preventing TXA2 formation; platelets can't synthesize a new enzyme; increases bleeding time, decreases TXA2 and prostaglandins

Use: antipyretic, analgesic, anti-inflammatory, decreases platelet aggregation; used post MI and post thrombotic stroke for secondary prevention

Adverse effects: gastric ulceration, tinnitus, acute renal failure, interstitial nephritis, upper GI bleeding, Reye syndrome in kids with viral infection

Overdose: hyperventilation and respiratory alkalosis that transitions to mixed metabolic acidosis-respiratory alkalosis

Antidote: alkalinize urine with sodium bicarbonate to promote renal excretion


ADP receptor inhibitors

Drugs: Clopidogrel, prasugrel, ticagrelor, ticlopidine

MOA: inhibit platelet aggregation by blocking ADP receptors; prevents GIIb/IIIa expression and prevents alpha granule secretion

Use: acute coronary syndrome, coronary stenting, decrease thrombotic stroke; used alongside aspirin

Adverse effects: neutropenia, TTP


cilostazol and dipyridamole

MOA: phosphodiesterase III inhibitors that inhibit platelet aggregation and vasodilate

Use: intermittent claudication, coronary vasodilation, prevent stroke or TIA when used in combo with aspirin, angina prophylaxis

Adverse effects: headache, facial flushing, hypotension, abdominal pain


GP IIb/IIIa inhibitors

Drugs: abciximab, eptifibatide, tirofiban

MOA: bind to GIIb/IIIa on activated platelets and prevent aggregation; prevents fibrin cross linking

Use: unstable angina, percutaneous transluminal coronary angioplasty

Adverse effects: bleeding, thrombocytopenia


Azathioprine, 6-mercaptopurine (6-MP), and 6-thioguanine (6-TG)

MOA: antimetabolite that inhibits DNA synthesis; purine analogs that decrease de novo purine synthesis

Use: prevent organ rejection, RA, IBD, SLE, steroid-refractory chronic disease

Adverse effects: myelosuppression, GI, liver; metabolized by xanthine oxidase and so have increased toxicity with allopurinol or febuxostat


Cladribine (2-CDA)

MOA: antimetabolite; purine analog

Use: hairy cell leukemia

Adverse effects: myelosuppression, nephrotoxicity, neurotoxicity



MOA: antimetabolite; pyrimiding analog that inhibits DNA polymerase

Use: AML, lymphomas

Adverse effects: leukopenia, thrombocytopenia, megaloblastic anemia



MOA: antimetabolite; pyrimidine analog; complexes with folic acid and inhibits thymidylate synthesis

Use: colon cancer, pancreatic cancer, BCC

Adverse effects: myelosuppression



MOA: folic acid analog; inhibits dihydrofolate reductase which is nevessary for making tymadine and thus DNA

Use: ALL, lymphomas, choriocarcinoma, sarcoma, ectopic pregnancy, medical abortion, RA, psoriasis, IBD, vasculitis

Adverse effects: myelosuppression, hepatotoxicity, mucositis, pulmonary fibrosis

Antidote: leucovorin can reverse the myelosuppression



MOA: induces free radical formation resulting in DNA strand breaks

Use; testicular cancer, Hodgkin lymphoma

Adverse effects: pulmonary fibrosis, skin hyperpigmentation, minimal myelosuppression



MOA: intercalates in DNA

Use: childhood tumors: Wilms tumor, Ewing sarcoma, rhabdomyosarcoma

Adverse effects: myelosuppression


Doxorubicin and daunorubicin

MOA: generates free radicals and intercalates in DNA

Use: sold tumors, leukemias, and lymphomas

Adverse effects: dilated cardiomyopathy (can prevent to some degree with chelators- dexrazoxane), myelosuppression, alopecia



used to reverse the myelosuppression seen with methotrexate therapy



chelator used to prevent the cardiotoxicity seen with doxorubicin therapy



MOA: alkylating agent- cross links DNA

Use: CML

Adverse effects: severe myelosuppression, pulmonary fibrosis


Cyclophosphamide and ifsosfamide

MOA: alkylating agent that cross links DNA; requires activation by liver

Use: solid tumors, leukemia, lymphoma

Adverse effects: myelosuppression, hemorrhagic cystitis, partically prevented with mesna



used to prevent the myelosuppression and hemorrhagic cystitis of cyclophosphamide therapy by binding to toxic metabolites



Drugs: carmustine, lomustine, semustine, streptozocin

MOA: alkylating agent- cross link DNA; cross the BBB

Use: brain tumors

Adverse effects: CNS toxicity


G-CSF (filgrastim)

used in conjunction with myelosuppressive chemotherapeutics to stimulate neutrophil production and maturation



MOA: xanthine oxidase inhibitor

Use: used to prevent acute tumor lysis syndrome where a bunch of cells all die at once and release toxic substances


Oprelvekin (IL-11)

MOA: thrombopoeitic growth factor

Use: combat thrombocytopenia seen with chemotherapy



MOA: microtubule inhibitor; stabilizes MTs in M phase so that the mitotic spindle can't break down

Use: ovarian and breast carcinoma

Adverse effects: myelosuppression, alopecia, hypersensitivity


Vincristine and vinblastine

MOA: microtubule inhibitors; inhibit beta tubulin polymerization preventing mitotic spindle formation

Use: solid tumors, leukemias, hodgkin and non-hodgkin lymphoma

Adverse effects: neurotoxicity for vincristine, myelosuppression for vinblastine